Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

COVID-19 and therapy with essential oils having antiviral, anti-inflammatory, and immunomodulatory properties

Coronavirus disease of 2019 (COVID-19) has emerged as a global health threat. Unfortunately, there are very limited approved drugs available with established efficacy against the SARs-CoV-2 virus and its inflammatory complications. Vaccine development is actively being researched, but it may take over a year to become available to general public. Certain medications, for example, dexamethasone, antimalarials (chloroquine/hydroxychloroquine), antiviral (remdesivir), and IL-6 receptor blocking monoclonal antibodies (tocilizumab), are used in various combinations as off-label medications to treat COVID-19. Essential oils (EOs) have long been known to have anti-inflammatory, immunomodulatory, bronchodilatory, and antiviral properties and are being proposed to have activity against SARC-CoV-2 virus. Owing to their lipophilic nature, EOs are advocated to penetrate viral membranes easily leading to membrane disruption. Moreover, EOs contain multiple active phytochemicals that can act synergistically on multiple stages of viral replication and also induce positive effects on host respiratory system including bronchodilation and mucus lysis. At present, only computer-aided docking and few in vitro studies are available which show anti-SARC-CoV-2 activities of EOs. In this review, role of EOs in the prevention and treatment of COVID-19 is discussed. A discussion on possible side effects associated with EOs as well as anti-corona virus claims made by EOs manufacturers are also highlighted. Based on the current knowledge a chemo-herbal (EOs) combination of the drugs could be a more feasible and effective approach to combat this viral pandemic

Year of Publication: 2020
Contained in: Inflammopharmacology Vol. 28, No. 5 (2020), p. 1153-1161
All journal articles: Search for all articles in this journal
Language: English
Contributors: Asif, Muhammad | Author
Saleem, Mohammad
Saadullah, Malik
Yaseen, Hafiza Sidra
Al Zarzour, Raghdaa
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: Docking studies
Essential oils
Immunomodulatory
Journal Article
Review
SARC-CoV-2
Additional Keywords: Anti-Inflammatory Agents, Non-Steroidal
Antiviral Agents
Coronavirus Infections
Humans
Immunologic Factors
Oils, Volatile
Pandemics
Plants, Medicinal
Pneumonia, Viral
ISSN: 1568-5608
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Completed 08.10.2020
Date Revised 08.10.2020
published: Print-Electronic
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32803479
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1007/s10787-020-00744-0
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 04404nma a2200745 c 4500
001 NLM314715320
003 DE-601
005 20201009214726.0
007 cr uuu---uuuuu
008 200817s2020 000 0 eng d
024 7 |a 10.1007/s10787-020-00744-0  |2 doi 
028 5 2 |a pubmed20n1425.xml 
035 |a (DE-599)NLM32803479 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Asif, Muhammad 
245 1 0 |a COVID-19 and therapy with essential oils having antiviral, anti-inflammatory, and immunomodulatory properties  |h Elektronische Ressource 
300 |a Online-Ressource 
500 |a Date Completed 08.10.2020 
500 |a Date Revised 08.10.2020 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a Coronavirus disease of 2019 (COVID-19) has emerged as a global health threat. Unfortunately, there are very limited approved drugs available with established efficacy against the SARs-CoV-2 virus and its inflammatory complications. Vaccine development is actively being researched, but it may take over a year to become available to general public. Certain medications, for example, dexamethasone, antimalarials (chloroquine/hydroxychloroquine), antiviral (remdesivir), and IL-6 receptor blocking monoclonal antibodies (tocilizumab), are used in various combinations as off-label medications to treat COVID-19. Essential oils (EOs) have long been known to have anti-inflammatory, immunomodulatory, bronchodilatory, and antiviral properties and are being proposed to have activity against SARC-CoV-2 virus. Owing to their lipophilic nature, EOs are advocated to penetrate viral membranes easily leading to membrane disruption. Moreover, EOs contain multiple active phytochemicals that can act synergistically on multiple stages of viral replication and also induce positive effects on host respiratory system including bronchodilation and mucus lysis. At present, only computer-aided docking and few in vitro studies are available which show anti-SARC-CoV-2 activities of EOs. In this review, role of EOs in the prevention and treatment of COVID-19 is discussed. A discussion on possible side effects associated with EOs as well as anti-corona virus claims made by EOs manufacturers are also highlighted. Based on the current knowledge a chemo-herbal (EOs) combination of the drugs could be a more feasible and effective approach to combat this viral pandemic 
611 2 7 |a Journal Article  |2 gnd 
611 2 7 |a Review  |2 gnd 
653 2 |a Anti-Inflammatory Agents, Non-Steroidal  |6 D000894  |a adverse effects  |6 Q000009  |a *therapeutic use  |6 Q000627 
653 2 |a Antiviral Agents  |6 D000998  |a adverse effects  |6 Q000009  |a *therapeutic use  |6 Q000627 
653 2 |a Coronavirus Infections  |6 D018352  |a *drug therapy  |6 Q000188 
653 2 |a Humans  |6 D006801 
653 2 |a Immunologic Factors  |6 D007155  |a adverse effects  |6 Q000009  |a *therapeutic use  |6 Q000627 
653 2 |a Oils, Volatile  |6 D009822  |a adverse effects  |6 Q000009  |a *therapeutic use  |6 Q000627 
653 2 |a Pandemics  |6 D058873 
653 2 |a Plants, Medicinal  |6 D010946  |a chemistry  |6 Q000737 
653 2 |a Pneumonia, Viral  |6 D011024  |a *drug therapy  |6 Q000188 
655 7 |a Docking studies  |2 gnd 
655 7 |a Essential oils  |2 gnd 
655 7 |a Immunomodulatory  |2 gnd 
655 7 |a SARC-CoV-2  |2 gnd 
655 7 |a Anti-Inflammatory Agents, Non-Steroidal  |2 gnd 
655 7 |a Antiviral Agents  |2 gnd 
655 7 |a Immunologic Factors  |2 gnd 
655 7 |a Oils, Volatile  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 1 |A f  |a Review 
689 0 |5 DE-601 
689 1 0 |a Docking studies 
689 1 1 |a Essential oils 
689 1 2 |a Immunomodulatory 
689 1 3 |a SARC-CoV-2 
689 1 |5 DE-601 
689 2 0 |a Anti-Inflammatory Agents, Non-Steroidal 
689 2 1 |a Antiviral Agents 
689 2 2 |a Immunologic Factors 
689 2 3 |a Oils, Volatile 
689 2 |5 DE-601 
700 1 |a Saleem, Mohammad 
700 1 |a Saadullah, Malik 
700 1 |a Yaseen, Hafiza Sidra 
700 1 |a Al Zarzour, Raghdaa 
773 0 8 |i in  |t Inflammopharmacology  |g Vol. 28, No. 5 (2020), p. 1153-1161  |q 28:5<1153-1161  |w (DE-601)NLM090689038  |x 1568-5608 
856 4 1 |u http://dx.doi.org/10.1007/s10787-020-00744-0  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 28  |j 2020  |e 5  |b 28  |c 10  |h 1153-1161